Laquinimod arrests experimental autoimmune encephalomyelitis by activating the aryl hydrocarbon receptor

Laquinimod is an oral drug currently being evaluated for the treatment of relapsing, remitting, and primary progressive multiple sclerosis and Huntington’s disease. Laquinimod exerts beneficial activities on both the peripheral immune system and the CNS with distinctive changes in CNS resident cell...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Proc Natl Acad Sci U S A
Hauptverfasser: Kaye, Joel, Piryatinsky, Victor, Birnberg, Tal, Hingaly, Tal, Raymond, Emanuel, Kashi, Rina, Amit-Romach, Einat, Caballero, Ignacio S., Towfic, Fadi, Ator, Mark A., Rubinstein, Efrat, Laifenfeld, Daphna, Orbach, Aric, Shinar, Doron, Marantz, Yael, Grossman, Iris, Knappertz, Volker, Hayden, Michael R., Laufer, Ralph
Format: Artigo
Sprache:Inglês
Veröffentlicht: National Academy of Sciences 2016
Schlagworte:
PNAS Plus
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5068259/
https://ncbi.nlm.nih.gov/pubmed/27671624
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.1607843113
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge